ライフサイエンスコーパス: diastolic dysfunction

1 (92 with HFNEF and 230 with asymptomatic LV diastolic dysfunction).

2 /or reduced global longitudinal strain, with diastolic dysfunction).

3 g, sympatho-vagal imbalance, arrhythmias and diastolic dysfunction.

4 , and 7 patients (29%) met the definition of diastolic dysfunction.

5 asis and cellular remodeling, which leads to diastolic dysfunction.

6 ciated with left ventricular hypertrophy and diastolic dysfunction.

7 lthough MS seems to be associated with worse diastolic dysfunction.

8 chanical mechanism which may partly underlie diastolic dysfunction.

9 r hypertrophy, left ventricular systolic and diastolic dysfunction.

10 iated with cardiac hypertrophy, fibrosis and diastolic dysfunction.

11 It appears to be associated with diastolic dysfunction.

12 r impaired fluid dynamics may be a source of diastolic dysfunction.

13 on in thin-filament HCM, reflecting profound diastolic dysfunction.

14 ats (SHAM) and aortic-banded rats exhibiting diastolic dysfunction.

15 associated with echocardiographic indexes of diastolic dysfunction.

16 s, such as increased myocardial stiffness or diastolic dysfunction.

17 herefore likely to be a major contributor to diastolic dysfunction.

18 RDN reduces BP, HR, and LV mass and improves diastolic dysfunction.

19 d by nondilated left or right ventricle with diastolic dysfunction.

20 entricular ejection fraction and evidence of diastolic dysfunction.

21 Ca(2+) sensitivity, severe hypertrophy, and diastolic dysfunction.

22 significantly lower values in patients with diastolic dysfunction.

23 r pressure overload, leading to fibrosis and diastolic dysfunction.

24 ertension, left ventricular hypertrophy, and diastolic dysfunction.

25 SCM and LAD MI show severe diastolic dysfunction.

26 from mice with metabolic syndrome-associated diastolic dysfunction.

27 tolerance, a phenotype often associated with diastolic dysfunction.

28 post ASO and are likely to contribute to LV diastolic dysfunction.

29 s is related to changes in right ventricular diastolic dysfunction.

30 ar heart disease often have left ventricular diastolic dysfunction.

31 in post-myocardial infarction patients with diastolic dysfunction.

32 pporting a titin-based mechanism for in vivo diastolic dysfunction.

33 mechanisms underlying arrhythmogenicity and diastolic dysfunction.

34 mice developed fibrotic cardiomyopathy with diastolic dysfunction.

35 ular hypertrophy, interstitial fibrosis, and diastolic dysfunction.

36 lyphenols prevent myocardial hypertrophy and diastolic dysfunction.

37 left ventricular hypertrophy, and associated diastolic dysfunction.

38 l prevented left ventricular hypertrophy and diastolic dysfunction.

39 CE2KO hearts and are likely mediators of the diastolic dysfunction.

40 cterized by left ventricular hypertrophy and diastolic dysfunction.

41 be a valuable target for the treatment of LV diastolic dysfunction.

42 nary hypertension (PH), and left ventricular diastolic dysfunction.

43 ing and an increase in Tei index, suggesting diastolic dysfunction.

44 tropic stress, in association with continued diastolic dysfunction.

45 tion between diffuse myocardial fibrosis and diastolic dysfunction.

46 osolic calcium reuptake kinetics, indicating diastolic dysfunction.

47 ion and contribution to cardiac fibrosis and diastolic dysfunction.

48 frequently associated with left ventricular diastolic dysfunction.

49 rated rats and aortic-banded rats exhibiting diastolic dysfunction.

50 in both normal animals and a pig model with diastolic dysfunction.

51 patients with AD present with an anticipated diastolic dysfunction.

52 reasing the compliance of titin in mice with diastolic dysfunction.

53 l or unrecognized, with a high prevalence of diastolic dysfunction.

54 239.9 vs. 576.7 +/- 472.9 events h(-1) ) and diastolic dysfunction (0.008 +/- 0.004 vs. 0.027 +/- 0.0

55 , and mitral inflow patterns consistent with diastolic dysfunction (1.95 +/- 0.05 FA versus 1.52 +/-

56 prevalent (29.7%) form of cTOD, followed by diastolic dysfunction (21.3%), left atrial enlargement (

57 s(-1)) than in patients with asymptomatic LV diastolic dysfunction (25.33+/-6.06% and 1.37+/-0.33 s(-

58 nd E/e' ratios; 2) their roles in diagnosing diastolic dysfunction; 3) prognostic implications of abn

59 hypertrophy (61% and 39%, respectively) and diastolic dysfunction (35% and 36%, respectively) than h

60 Nontransgenic TAC developed diastolic dysfunction (65% increase in E/A ratio), where

61 nt and high prevalence of LV hypertrophy and diastolic dysfunction; a subclinical systolic dysfunctio

62 ng pressure during exercise in patients with diastolic dysfunction after myocardial infarction.

63 and fibrosis biomarkers, and the severity of diastolic dysfunction all increased with severity of RVD

64 ventricular arrhythmic burden, and systolic/diastolic dysfunction (all p < 0.05).

65 ation, cardiac hypertrophy, and systolic and diastolic dysfunction, although the pathogenesis of thes

66 model may increase late I(Na), resulting in diastolic dysfunction amenable to treatment with ranolaz

67 e odds ratios (95% confidence intervals) for diastolic dysfunction among individuals with prediabetes

68 tivariable echocardiographic Cox model, only diastolic dysfunction and 2D-GLS remained as independent

69 h are resistant to PKGIalpha oxidation, have diastolic dysfunction and a diminished ability to couple

70 ial volume (LAV) increase is an indicator of diastolic dysfunction and a surrogate marker of signific

71 re at year 0 was associated with both severe diastolic dysfunction and abnormal relaxation 5 years la

72 mposite endpoint in participants with severe diastolic dysfunction and abnormal relaxation were 4.3 (

73 tic cardiomyopathy is characterized by early diastolic dysfunction and adverse left ventricular (LV)

74 y play a central role in the pathogenesis of diastolic dysfunction and arrhythmia.

75 Finally, Myr improved diastolic dysfunction and attenuated histological abnorm

76 independent of blood pressure, by improving diastolic dysfunction and by modulating cardiac hypertro

77 dings may contribute to the left ventricular diastolic dysfunction and cardiac reserve function impai

78 04, and December 31, 2005, and had grade 2-4 diastolic dysfunction and ejection fraction >/=50% were

79 r filling ratio (E/A), indicative of grade 1 diastolic dysfunction and emphasizing the importance of

80 ertension, left ventricular hypertrophy, and diastolic dysfunction and had higher myocardial natriure

81 )-related cardiomyopathy is characterized by diastolic dysfunction and hyperdynamic features.

82 which may play a role in the development of diastolic dysfunction and inappropriate shortness of bre

83 lood transfusions; P<0.05 for both), whereas diastolic dysfunction and increased filling pressures we

84 Diastolic dysfunction and left ventricular remodeling ar

85 Seventy patients with diastolic dysfunction and near normal left ventricular e

86 cular chamber levels showed that this causes diastolic dysfunction and other symptoms of heart failur

87 on, whereas deficient phosphorylation causes diastolic dysfunction and phenotypes resembling HFpEF.

88 ks of a high-salt diet, 31 of 38 rats showed diastolic dysfunction and preserved ejection fraction al

89 The aging myopathy manifests itself with diastolic dysfunction and preserved ejection fraction.

90 ctions, which are linked to left ventricular diastolic dysfunction and remodeling.

91 Left ventricular diastolic dysfunction and right ventricular dilatation a

92 ing LV GLS is associated with more severe LV diastolic dysfunction and RV systolic and diastolic dysf

93 sm in experimental models of hypertrophy and diastolic dysfunction and the role of the Ang II type 1

94 Recurrent AF, was associated with increased diastolic dysfunction and vasopressor use and a greater

95 sociations of these arterial parameters with diastolic dysfunction and ventricular-arterial coupling

96 orubicin-injected fish developed ventricular diastolic dysfunction and worsening global cardiac funct

97 left ventricular ejection fraction >50%, and diastolic dysfunction) and 60 patients with stage B HF (

98 ontributes to the development of age-related diastolic dysfunction, and (2) initiation of late-life e

99 ce) develop progressive myocardial fibrosis, diastolic dysfunction, and adverse cardiac remodeling.

100 c hypertrophy, left ventricular systolic and diastolic dysfunction, and autophagy in mice.

101 layed decreased ventricular dimensions, mild diastolic dysfunction, and enhanced systolic function, w

102 II, left ventricular ejection fraction >50%, diastolic dysfunction, and exertional E/e' >13), excludi

103 ioration of Ang-induced cardiac hypertrophy, diastolic dysfunction, and fibrosis, despite the absence

104 e combined rates of LV systolic dysfunction, diastolic dysfunction, and heart failure.

105 EF exacerbates left ventricular hypertrophy, diastolic dysfunction, and HF.

106 ventricular abnormalities, such as low GLS, diastolic dysfunction, and hypertrophy (log-rank P<0.000

107 of myocardial substrate selection, reversed diastolic dysfunction, and normalized blood glucose leve

108 ardial fibrosis, abnormal perfusion reserve, diastolic dysfunction, and only rarely myocardial iron o

109 LV diastolic dysfunction and RV systolic and diastolic dysfunction, and provides incremental prognost

110 iated feature of SCA that is associated with diastolic dysfunction, anemia, and high NT-proBNP.

111 Increased left ventricular (LV) mass and diastolic dysfunction are associated with cardiovascular

112 LVH and diastolic dysfunction are associated with elevated sympa

113 Both PH and diastolic dysfunction are associated with marked abnorma

114 echocardiography disclosed left ventricular diastolic dysfunction as unexpected cardiogenic cause of

115 ressive development of left ventricular (LV) diastolic dysfunction, as assessed by markers of LV dias

116 tors of mortality or major morbidity: severe diastolic dysfunction, as evidenced by restrictive filli

117 pertrophy and fibrosis with normalization of diastolic dysfunction assessed by pressure-volume loop a

118 tive physician be alerted to the presence of diastolic dysfunction, be knowledgeable of the diastolic

119 mal Doppler E-wave filling patterns indicate diastolic dysfunction but are indistinguishable from the

120 therapy can be of value for the treatment of diastolic dysfunction, but there is a paucity of data ev

121 function (via echocardiography) demonstrated diastolic dysfunction by 2 weeks (20% increase in E/E'),

122 ial energy reserve is limited, contribute to diastolic dysfunction by recruiting cross-bridges, even

123 (b) elevate diastolic [Ca]i, contributing to diastolic dysfunction; (c) cause triggered arrhythmias;

124 3 loss did not affect survival, systolic and diastolic dysfunction, cardiac fibrosis, and cardiomyocy

125 r afterload leads to myocardial hypertrophy, diastolic dysfunction, cellular remodelling and compromi

126 ncreased TAG accumulation, lipotoxicity, and diastolic dysfunction comparable to wild-type mice.

127 D increment) had a stronger association with diastolic dysfunction compared with SBP.

128 ated with more global LV thickening and with diastolic dysfunction, compared to WES feeding alone.

129 of prospective risk markers associated with diastolic dysfunction could allow for targeted primary p

130 Diastolic dysfunction could be reversed by ranolazine, p

131 normalities result in progressive and severe diastolic dysfunction, culminating in heart failure.

132 10) compared with patients with isolated LV diastolic dysfunction (DD) (n = 10) and control subjects

133 Left ventricular diastolic dysfunction (DD) is a key determinant of outco

134 Diastolic dysfunction (DD) is an independent predictor o

135 Left ventricular diastolic dysfunction (DD) is common after myocardial in

136 They contribute to myocardial diastolic dysfunction (DD) through collagen deposition o

137 eft ventricular systolic dysfunction (LVSD), diastolic dysfunction (DD), pulmonary arterial hypertens

138 erved ejection fraction is often preceded by diastolic dysfunction (DD).

139 associated with echocardiographic markers of diastolic dysfunction (DD).

140 oke volume (2.0%, P=0.002), left ventricular diastolic dysfunction (deceleration time [0.9%, P=0.03]

141 hic and clinical variables, left ventricular diastolic dysfunction defined as increased mitral E-to-s

142 corrected abnormal myocardial relaxation in diastolic dysfunction disease models in vitro and in viv

143 ps, patients with mild, moderate, and severe diastolic dysfunction displayed significantly reduced no

144 nt mechanism underlying cardiac fibrosis and diastolic dysfunction during increased renin-angiotensin

145 This study suggests that elevated markers of diastolic dysfunction during pre-LTx echocardiographic e

146 mal levels (0.018 +/- 0.002 s(-1)), reversed diastolic dysfunction (E/E' 14 +/- 1), and normalized bl

147 Twenty-three of them correlated with diastolic dysfunction (E/e') and 5 with left atrial volu

148 deformation indices with Doppler indices of diastolic dysfunction, functional capacity, biomarkers,

149 d ejection fraction and their correlation to diastolic dysfunction, functional class, pathophysiologi

150 astolic dysfunction, be knowledgeable of the diastolic dysfunction grading system and understand the

151 Participants with diastolic dysfunction had higher ECV (0.49 +/- 0.07 vs 0

152 cardiomyopathy with severe left ventricular diastolic dysfunction has been associated with marked ex

153 Heart failure (HF) with diastolic dysfunction has been attributed to increased m

154 ar exercise training ameliorates age-related diastolic dysfunction; however, the underlying mechanism

155 - and sex-matched hypertensive patients with diastolic dysfunction (hypertensive heart disease) but n

156 NCA) limits cardiomyocyte hypertrophy and LV diastolic dysfunction in a mouse model of diabetes melli

157 coronary perfusion are likely mechanisms of diastolic dysfunction in aged rats.

158 Late systolic load has been shown to cause diastolic dysfunction in animal models.

159 t ventricular hypertrophy (LVH) and systolic/diastolic dysfunction in asymptomatic patients with HF r

160 emporary measures of longitudinal strain and diastolic dysfunction in defining HF stages is unclear.

161 cardiomyopathy with severe left ventricular diastolic dysfunction in end-stage disease.

162 tex generation is an unreported mechanism of diastolic dysfunction in HCM and probably other causes o

163 Diastolic dysfunction in heart failure patients is evide

164 Although macitentan did not modulate diastolic dysfunction in HFpEF, it significantly reduced

165 rdial fibrosis in SCA mice, but the cause of diastolic dysfunction in humans with SCA is unknown.

166 Echocardiography detected evidence of diastolic dysfunction in hypertensive mice that improved

167 is associated with incipient LV systolic and diastolic dysfunction in middle age.

168 of RV remodeling exist in obesity and (2) LV diastolic dysfunction in obesity is related to RV hypert

169 ar mass index or improve certain measures of diastolic dysfunction in patients with chronic kidney di

170 known whether the myofilament contributes to diastolic dysfunction in patients with concentric remode

171 iew summarizes the underlying mechanisms for diastolic dysfunction in patients with mitral and aortic

172 However, it could contribute to diastolic dysfunction in patients with sepsis.

173 Diastolic dysfunction in response to hypertrophy is a ma

174 s a novel mechanism that appears to underlie diastolic dysfunction in SCA.

175 ess promotes fibrosis and contributes to the diastolic dysfunction in the aging heart.

176 risk markers, and prognosis associated with diastolic dysfunction in the Coronary Artery Risk Develo

177 Ang 1-7 completely rescued the diastolic dysfunction in the db/db model.

178 ew focuses on recent findings on the role of diastolic dysfunction in the perioperative period and on

179 The precise mechanism of LV diastolic dysfunction in the presence of myocardial fibr

180 have added value to assess right ventricular diastolic dysfunction in this population.

181 fusion) resulted in more severe systolic and diastolic dysfunction in TIMP4(-/-) mice with enhanced i

182 hypertrophy and remodeling and systolic and diastolic dysfunction in transverse aortic constriction

183 Exogenous sFLT1 alone caused diastolic dysfunction in wild-type mice, and profound sy

184 ay contribute to increased susceptibility to diastolic dysfunction in women.

185 Diastolic dysfunction in young adults is associated with

186 Risk factors for persistent diastolic dysfunction include higher pre-BAVP LV mass z-

187 correlated with echocardiographic indexes of diastolic dysfunction including a higher mitral E-wave z

188 cus on what is known concerning pre-clinical diastolic dysfunction, including definitions, staging, e

189 lvement, those with NAFLD had features of LV diastolic dysfunction, including higher E-to-e' ratio an

190 ABSTRACT: The risk for diastolic dysfunction increases with advancing age.

191 Right ventricular diastolic dysfunction influences outcomes in pulmonary a

192 Incorporation of longitudinal strain and diastolic dysfunction into the Stage B definition reclas

193 Age-related diastolic dysfunction is a major factor in the epidemic

194 Diastolic dysfunction is a poorly understood but clinica

195 Left ventricular diastolic dysfunction is an asymptomatic condition assoc

196 Diastolic dysfunction is an independent predictor of mor

197 Left ventricular diastolic dysfunction is an underestimated disease with

198 Diastolic dysfunction is associated with microscopic myo

199 Ang II- and PE-induced hypertrophy and diastolic dysfunction is associated with reduced glucose

200 Diastolic dysfunction is frequently seen after myocardia

201 Diastolic dysfunction is general to all idiopathic dilat

202 usion requirements, whereas left ventricular diastolic dysfunction is predominantly correlated with i

203 Although diastolic dysfunction is widely considered a key pathoph

204 mean 6 cm/s [SD 1.2] versus FGR 5.3 [1]) and diastolic dysfunction (isovolumic relaxation time: contr

205 SAM-WD had developed HFpEF, characterized by diastolic dysfunction, left ventricular hypertrophy, lef

206 uction, left ventricular hypercontractility, diastolic dysfunction, left-atrial enlargement and left

207 normalities, including left ventricular (LV) diastolic dysfunction, longitudinal LV systolic dysfunct

208 Z value, +0.45 +/- 0.49, P < 0.001) and more diastolic dysfunction (lower E', Z value, -0.7 +/- 1.02,

209 er left ventricular ejection fraction, worse diastolic dysfunction, lower blood pressure and cardiac

210 ce ameliorated left ventricular hypertrophy, diastolic dysfunction, lung congestion, and myocardial o

211 We investigated left ventricular diastolic dysfunction (LVDD) and its relationship with c

212 olic dysfunction (LVSD) and left ventricular diastolic dysfunction (LVDD).

213 nary venous pressure due to left ventricular diastolic dysfunction may contribute by exacerbating cap

214 and stroke volume (77 mL) were normal, while diastolic dysfunction (medial E/e', 16; deceleration tim

215 Pediatric PH patients exhibit LV diastolic dysfunction most consistent with impaired rela

216 PH patients had evidence of LV diastolic dysfunction, most consistent with impaired LV

217 s confirmed that the abnormalities including diastolic dysfunctions, myocardial fibrosis and metaboli

218 graphically proved mild, moderate, or severe diastolic dysfunction (n = 30, 44-73 years).

219 ortening this segment is sufficient to cause diastolic dysfunction need to be established.

220 Diastolic dysfunction occurred in both affected males an

221 Decline in FVC was associated with diastolic dysfunction (odds ratio, 3.39; 95% confidence

222 with E/A ratio (beta +/- SE: 0.12 +/- 0.04), diastolic dysfunction (odds ratio: 0.33; 95% confidence

223 low E/A ratio (beta +/- SE: -0.17 +/- 0.07), diastolic dysfunction (odds ratio: 7.8; 95% confidence i

224 consisting of asymptomatic subjects with LV diastolic dysfunction of similar age, sex, and LV ejecti

225 erstitium, triggering fibrosis, systolic and diastolic dysfunction of stressed hearts.

226 ted, and the impact of left ventricular (LV) diastolic dysfunction on RV hypertrophy is unknown, we a

227 The influence of arterial afterload and diastolic dysfunction on the hemodynamic presentation of

228 lar resistance index was not associated with diastolic dysfunction or Ea/Ees.

229 Whether this miRNA might contribute to diastolic dysfunction or other forms of heart disease is

230 ricular dilation or hypertrophy, systolic or diastolic dysfunction, or both, or various forms of cong

231 ntricular hypertrophy, systolic dysfunction, diastolic dysfunction, or left atrial enlargement).

232 ensive clinical models, 2D-GLS (p < 0.0001), diastolic dysfunction (p < 0.01), the pathologic free li

233 is and evidence of isolated left ventricular diastolic dysfunction (p < 0.05).

234 IPCAR was positively associated with grade I diastolic dysfunction (P < 0.050 for all logistic models

235 CV values (>/=0.40) were more likely to have diastolic dysfunction (P = .003) and increased left atri

236 rial volume (P = .002) and with the grade of diastolic dysfunction (P = .016).

237 o <55% and were more likely to have advanced diastolic dysfunction (P=0.002).

238 This improvement in diastolic dysfunction parameters in aldosterone-infused

239 e effect may be partially mediated through a diastolic dysfunction pathway that includes left ventric

240 Pre-clinical diastolic dysfunction (PDD) has been broadly defined as

241 Preclinical diastolic dysfunction (PDD) has been broadly defined as

242 effects in the heart in vivo that lead to a diastolic dysfunction phenotype.

243 Diastolic dysfunction portends early mortality in SCA.

244 e sleep apnea, high-level physical training, diastolic dysfunction, predisposing gene variants, hyper

245 SD, 0.3) years between examinations 1 and 2, diastolic dysfunction prevalence increased from 23.8% (9

246 x and includes left ventricular systolic and diastolic dysfunction, pulmonary vascular disease, endot

247 was inversely correlated to the severity of diastolic dysfunction (R = -0.61, P < .001).

248 th LV E/e' as an echocardiographic marker of diastolic dysfunction (r = 0.54, P < 0.05).

249 othesized that pediatric PH patients have LV diastolic dysfunction, related to adverse pulmonary hemo

250 Diastolic dysfunction represents a combination of impair

251 d end-systolic chamber elastance, as well as diastolic dysfunction seen at the level of the whole hea

252 lation, pathological myocyte remodeling, and diastolic dysfunction, starting from prediabetes.

253 ad lower LS, greater dyssynchrony, and early diastolic dysfunction, supporting the notion that obesit

254 -deficient mice, however, showed exacerbated diastolic dysfunction, sustained elevation of membrane-t

255 y, smaller left atria, and less systolic and diastolic dysfunction than FG+ probands with HCM.

256 ure, seems to contribute to the systolic and diastolic dysfunction that characterizes the disease.

257 his is often accompanied by left ventricular diastolic dysfunction that has also been a strong indepe

258 lar thickening at 4 weeks of age, as well as diastolic dysfunction that progressed with age, in Hyal2

259 ng that cardiac oxidative stress may mediate diastolic dysfunction through altering the contractile a

260 The latter affects left ventricular diastolic dysfunction through macrophage infiltration, r

261 expression contributes mainly to myocardial diastolic dysfunction through mitochondrial apoptosis, L

262 Diastolic dysfunction underlies HFpEF; therefore, elucid

263 More importantly, diastolic dysfunction usually improves with timely surgi

264 Diastolic dysfunction was associated with development of

265 Diastolic dysfunction was associated with incident heart

266 Furthermore, LV diastolic dysfunction was associated with increased LV f

267 Diastolic dysfunction was defined using Doppler and tiss

268 Diabetes mellitus-induced LV diastolic dysfunction was evident on echocardiography-de

269 diameter and left ventricular mass although diastolic dysfunction was more pronounced in OB/MS+ than

270 95% CI 2.07-10.9); however, left-ventricular diastolic dysfunction was not (P>0.05).

271 nts included in the primary analysis, severe diastolic dysfunction was present in 1.1% and abnormal r

272 Diastolic dysfunction was present in 26% of patients wit

273 Diastolic dysfunction was present in 66% of gradable par

274 Baseline diastolic dysfunction was present in 770 patients (72.3%

275 Diastolic dysfunction was present in WES+DHA rats compar

276 The risk of diastolic dysfunction was significantly higher in overwe

277 ial volume index (an indicator of chronic LV diastolic dysfunction) was significantly increased at 2

278 rdial stiffness, consistent with upheld(101) diastolic dysfunction, was confirmed by an atomic force

279 ry capillary wedge pressure, consistent with diastolic dysfunction, was present in 15 patients (75%).

280 more, parameters reflecting left ventricular diastolic dysfunction were more pronounced in advanced N

281 Age and diastolic dysfunction were positively and statin use was

282 left atrial dimension (19%; indicative of LV diastolic dysfunction) when compared with WT.

283 excess left ventricular (LV) hypertrophy and diastolic dysfunction; whether this occurs also in secon

284 (left ventricular hypertrophy, fibrosis and diastolic dysfunction), while the phenotype of vascular

285 in db/db mice, but protected from myocardial diastolic dysfunction, while causing left ventricular ch

286 diabetic cardiac hypertrophy, fibrosis, and diastolic dysfunction, while preserving normal cardiac g

287 xpressing alpha-TM-D137L showed systolic and diastolic dysfunction with decreased myofilament Ca(2+)

288 sed passive stiffness is sufficient to cause diastolic dysfunction with exercise intolerance.

289 eas deficient cMyBP-C phosphorylation causes diastolic dysfunction with HFpEF in cMyBP-C(t3SA) mice.

290 t-HT demonstrated biventricular systolic and diastolic dysfunction with most prominent impairment in

291 progressive left ventricular hypertrophy and diastolic dysfunction with preservation of systolic func

292 ial (LA) enlargement and dysfunction, and LV diastolic dysfunction with preserved systolic function,

293 d by progressive left atrial enlargement and diastolic dysfunction with preserved systolic function.

294 rdiography showed concentric hypertrophy and diastolic dysfunction, with preserved systolic function

295 mpaired transmitral flow indicative of early diastolic dysfunction within 5 weeks.

296 tinguish patients with HFpEF from those with diastolic dysfunction without heart failure.

297 has been broadly defined as left ventricular diastolic dysfunction without the diagnosis of congestiv

298 ly defined as subjects with left ventricular diastolic dysfunction, without the diagnosis of congesti

299 ral chemoreflex pathway in HFpEF exacerbates diastolic dysfunction, worsens sympatho-vagal imbalance

300 ter, mean limb lead QRS voltage, and grade 3 diastolic dysfunction yielded excellent discriminatory c